title: Malignancies and catastrophic anti-phospholipid syndrome.
abstract: The catastrophic anti-phospholipid (Asherson's) syndrome (CAPS) is characterised by the rapid chronological development of fulminant thrombotic complications that predominantly affect small vessels and differs from the anti-phospholipid syndrome in its accelerated systemic involvement leading to multi-organic failure. Malignancy may play a pathogenic role in patients with CAPS, whereas infections are more important as triggering factors in patients without malignancies. CAPS patients with malignancies are generally older than CAPS patients without malignancies; they generally have the worst prognosis of the entire CAPS cohort.
authors.affiliation: Medical Clinic III, Institute of Transfusion Medicine, University Hospital, Johann Wolfgang Goethe-University, Frankfurt, Germany. Wolfgang.miesbach@kgu.de
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Miesbach
mesh_terms: D000367:Age Factors; D017152:Antibodies, Antiphospholipid / Q000097:blood; D016736:Antiphospholipid Syndrome / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D002388:Catastrophic Illness; D005858:Germany; D019337:Hematologic Neoplasms / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D006801:Humans; D015994:Incidence; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000150:complications*; D010956:Plasmapheresis; D015995:Prevalence; D011379:Prognosis; D012042:Registries; D012307:Risk Factors; D013927:Thrombosis / Q000097:blood / Q000276:immunology*; D016896:Treatment Outcome
chemical_list: D017152:Antibodies, Antiphospholipid